Neuromodulation Systems Market by Type (Spinal Cord, Sacral Nerve, Vagus Nerve, Deep Brain Stimulation), Application (Parkinson's Disease, Tremor, Depression, Epilepsy, Gastroparesis, Obesity, Psychiatry, Neurology, Pediatrics) - Global Forecast to 2030

The Neuromodulation Systems Market is projected to reach $10.29 billion by 2030, at a CAGR of 8.2% from 2024 to 2030. Neuromodulation devices are medical tools used to modify the activity of the nervous system by altering the electrical or chemical signals within the brain and spinal cord. These devices are used to treat a wide range of conditions, such as chronic pain, movement disorders, and depression, by changing how nerve cells communicate and transmit signals.

Neuromodulation devices can be implantable, such as deep brain stimulators or spinal cord stimulators, or non-invasive, such as transcutaneous electrical nerve stimulation (TENS) units. Neuromodulation aims to provide targeted and effective relief to specific areas of the nervous system in a safe and controlled manner. The specific type of neuromodulation device used depends on the target area and the condition being treated.

For example, deep brain stimulation (DBS) devices are used to treat movement disorders, such as Parkinson's disease, by delivering electrical stimulation to specific regions of the brain. On the other hand, spinal cord stimulation (SCS) devices are used to relieve chronic pain by delivering electrical stimulation to the spinal cord.

The high prevalence of neurological disorders and nerve injuries, advancements in neuromodulation & neurostimulation technologies, and expanding applications of neuromodulator systems are the factors driving the growth of this market. Furthermore, emerging economies and the increasing demand for non-invasive devices are expected to offer significant growth opportunities for market expansion. However, the shortage of skilled healthcare professionals and regulatory barriers and recall of neuromodulator systems pose a major challenge to the growth of the neuromodulation systems market.

Click here to: Get a Free Sample Copy of this report

High Prevalence of Neurological Disorders and Nerve Injuries is Driving the Market’s Growth

The rising prevalence of neurological disorders and nerve injuries is one of the factors driving the growth of the neuromodulation device market. According to the United Nations data updated in 2020, approximately 1 billion of the world’s population suffer from neurological disorders. According to Parkinson's Foundation, in the U.S., almost 90,000 people are diagnosed with Parkinson's every year. The number of people with Parkinson's is expected to reach 1.2 million by 2030. Neurological disorders, such as Parkinson's disease and epilepsy, can significantly impact an individual's quality of life, resulting in a high degree of disability. In addition, nerve injuries, such as spinal cord injuries, peripheral nerve injuries, and traumatic brain injuries, can also result in chronic pain and decreased mobility.

Traditionally, these conditions have been treated with medications, physical therapy, or surgery. However, these treatments are not always effective and can result in significant side effects. Neuromodulation devices offer a minimally invasive alternative for treating these conditions and have shown promising results in managing symptoms and improving function. The growth in the geriatric population drives the incidence rate of neurological disorders and nerve injuries, subsequently driving the demand for neuromodulation systems.

Emerging Economies in Asia-Pacific and Latin America Offer Significant Opportunities for the Market’s Growth

Emerging economies, such as India, China, and Brazil, have a large and growing population of individuals with neurological disorders and nerve injuries. According to Indian Stroke Association (ISA), the prevalence of stroke is rising in India, with nearly 1.8 million new cases reported annually. Stroke, headache disorders, and epilepsy are the leading contributors to neurological disorders burden in India.

These economies are also experiencing a significant increase in the aging population, which is a risk factor for many neurological conditions. Thus, there is a growing focus on developing and introducing neuromodulation devices, developing local manufacturing capabilities, introducing new and innovative devices, and establishing distribution and service networks in emerging economies to meet the growing demand for effective treatments for these conditions. Efforts are also underway to increase patient awareness and access to these devices in emerging economies by expanding public and private healthcare systems and educating and training healthcare professionals.

Key Findings in the Global Neuromodulation Systems Market Study:

Based on type, in 2024, the internal neuromodulation segment is expected to account for the largest share

The factors contributing to the large market share of this segment are the growing number of people with various conditions such as depression, chronic pain, and heart-related diseases. Internal neuromodulation devices are more effective than external devices as they can directly stimulate the target neural circuits, leading to better outcomes for patients. These devices are convenient for long-term use, can be customized according to patient needs, and increases patient compliance. The internal stimulation segment is further subsegmented into spinal cord stimulation, deep brain stimulation, sacral nerve stimulation, vagus nerve stimulation, and gastric electrical stimulation. In 2024, the spinal cord stimulation segment is expected to account for the largest share of the market.

North America Expected to be the Largest Regional Market in 2024

North America’s major market share is attributed to the high prevalence of neurological disorders, availability of advanced treatment options, well-established healthcare system, significant investments in healthcare, and the growth in the geriatric population. The region has a high prevalence of neurological disorders, such as chronic pain, depression, Parkinson's disease, and epilepsy, driving demand for effective treatments, including neuromodulation devices.

Furthermore, North America's well-developed healthcare system enables access to advanced treatment options, including neuromodulation devices. This has helped to increase patient awareness and access to these devices. Major players operating in the field of neuromodulation systems are from the U.S. Additionally, North America’s well-established healthcare system enables the development, introduction, and widespread adoption of advanced medical technologies, including neuromodulation devices. Also, the growth in the aging population results in the high prevalence of neurological conditions, which drives demand for effective treatments, including neuromodulation systems.

Key Players

The report includes a competitive landscape based on an extensive assessment of the key strategic growth strategies adopted by leading market players between 2020 and 2022. The key players profiled in the global neuromodulation systems market report include LivaNova PLC (U.K.), Nevro Corp. (U.S.), Medtronic plc (Ireland), Abbott Laboratories (U.S.), NeuroSigma, Inc. (U.S.), Neuronetics, Inc. (U.S.), NeuroPace, Inc. (U.S.), Bioventus Inc. (U.S.), MicroTransponder, Inc. (U.S.), Soterix Medical, Inc. (U.S.), Boston Scientific Corporation (U.S.), Synapse Biomedical Inc. (U.S.), and Aleva Neurotherapeutics SA (Switzerland).

Scope of the Report:

Neuromodulation Systems Market, by Type

• Internal Neuromodulation
  • Spinal Cord Stimulation (SCS), by Application
    • Failed Back Surgery Syndrome
    • Post-surgical Pain
    • Arachnoiditis
    • Other SCS Applications
  • Deep Brain Stimulation (DBS), by Application
    • Parkinson's Disease
    • Essential Tremor
    • Depression
    • Other DBS Applications
  • Sacral Nerve Stimulation, by Application
    • Urine incontinence
    • Fecal incontinence
  • Vagus Nerve Stimulation (VNS), by Application
    • Epilepsy
    • Depression
    • Other VNS Applications
  • Gastric Electrical Stimulation, by Application
    • Gastroparesis
    • Obesity
• External Neuromodulation
  • Transcranial Magnetic Stimulation (TMS), by Application
    • Psychiatry
    • Neurology
    • Pediatrics
    • Other TMS Applications
  • Transcutaneous Electrical Nerve Stimulation (TENS)
    • Depression
    • Other TENS Applications
  • Respiratory Electrical Stimulation

Note: (Other SCS Applications include heart pain (angina), injuries to the spinal cord, nerve-related pain, peripheral vascular disease, and complex regional pain syndrome)
(Other DBS Applications include Dystonia and obsessive-compulsive disorder (OCD) or Tourette disorder)
(Other VNS Applications include stroke and migraine)
(Other TMS Applications include anxiety and generalized anxiety disorder (GAD))
(Other TENS Applications include acute pain and chronic pain)

Neuromodulation Systems Market, by Geography

• North America
  • U.S.
  • Canada
• Europe
  • Germany
  • U.K.
  • France
  • Italy
  • Spain
  • Rest of Europe (RoE)
• Asia-Pacific (APAC)
  • China
  • Japan
  • India
  • Rest of APAC (RoAPAC)
• Latin America
  • Brazil
  • Mexico
  • Rest of Latin America (RoLATAM)
• Middle East & Africa

Key questions answered in the report: